Longer-term use and early initiation of Biogen Inc.’s experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) was effective in slowing disease progression, according to a new analysis by the company published on Wednesday.

Federal investigators on Wednesday recommended that the U.S. Food and Drug Administration revise its emergency use authorization (EUA) policies for tests to ensure better availability and quality during future infectious disease outbreaks.

The U.S. Food and Drug Administration has approved Fennec Pharmaceuticals Inc.’s intravenous therapy to prevent chemotherapy-induced hearing loss in children, according to the health regulator’s website.

Cooking chicken in cough medicine NyQuil is not only silly and unappetizing but can also be very unsafe, the U.S. Food and Drug Administration said, following the “sleepy chicken” TikTok challenge.

The United States government has sent out over 25 million of the updated COVID-19 booster shots, mostly from Pfizer/BioNTech, as production of the Moderna shot continues to ramp up, a federal health agency said on Tuesday.

The U.S. Food and Drug Administration’s (FDA) staff on Tuesday raised concerns over the safety of Spectrum Pharmaceutical’s experimental cancer drug and questioned the benefits it provided over existing therapies, dragging its shares 30%.

Cancer detection test maker Grail, acquired by Illumina Inc. last year despite ongoing antitrust challenges, on Tuesday said it would expand use of its flagship Galleri cancer diagnostic test through a new agreement with life insurer John Hancock, a division of Manulife Financial.

The FDA approved bluebird bio’s lentiviral vector (LVV) eli-cel Friday as the first therapy to slow the progression of neurologic dysfunction in juvenile boys with early, active cerebral adrenoleukodystrophy (CALD).

The FDA approved Mallinckrodt Pharmaceuticals’ Terlivaz (terlipressin) in adults with hepatorenal syndrome (HRS), making it the only FDA-approved drug for that indication in the U.S.

People in Europe should take whatever COVID-19 booster is available to them in the coming months, Emer Cooke, Executive Director of the European Medicines Agency (EMA), said in a Reuters Next Newsmaker interview, ahead of an expected autumn rise in infections.